Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,…
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open…
TORONTO, March 29, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty…
Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied…
Glen Rock, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”) is pleased…
KET01 Phase 2 Clinical Trial with Topline Results Expected Mid-YearMUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health…
-The distinction recognizes faculty who have demonstrated success in translating research into a commercial setting-BOSTON and ATHENS, Ga., March 28,…
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023…
Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca RatonBOCA RATON, Fla. and VIENNA, Austria, March…
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue…